Natera Q3 revenue $158.1M (+61% YoY), net loss $151.3M; raises FY2021 revenue guidance

Natera, Inc.

2022-Q3 EPS reported -$3.72 revenue$452,458,000

Revenue $158.1M (+61.1% YoY); product revenue $150.7M (+61.5%); tests processed 407,300 (+55.4%).
Net loss $151.3M (EPS -$1.63) vs loss $58.3M (-$0.72) in Q3 2020; operating loss $150.2M.
Raises 2021 revenue guidance to $615-625M from prior; expects gross margin 49-52%; SG&A $500-520M; R&D $240-260M.
Cash $1.0B; total debt $330.1M ($287.5M convertible notes principal; $50M credit line).
Launched Prospera Kidney/Heart/Lung; exclusive license from Aarhus University for colorectal cancer screening biobank.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.